Drug intelligence / Profile preview

TP-317

Development stage: Unknown
Lead developer: Thetis Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

TP-317 (also known as STB-317) is an oral small molecule therapy developed by Thetis Pharmaceuticals. It is a stabilized analog or derivative of Resolvin E1 (RvE1), a specialized pro-resolving mediator (SPM) derived from omega-3 fatty acids. TP-317 is designed to promote the resolution of inflammation and restore immune homeostasis by acting as an agonist of the BLT1 receptor (Leukotriene B4 receptor 1). By targeting the LTB4-BLT1 pathway, it aims to address unmet needs in chronic inflammatory conditions such as ulcerative colitis and Crohn's disease, as well as in solid tumor cancers. The drug has completed a Phase 1a study in healthy volunteers and is progressing into Phase 1b trials for ulcerative colitis.

Other names: Resolvin E1 analog

Targets

LTB4R (Leukotriene B4 Receptor 1)

Beyond the preview

Go deeper on TP-317.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TP-317.

Explore the full profile